VEGF-A and blood vessels: a beta cell perspective

Staels, Willem; Heremans, Yves; Heimberg, Henry; Leu, Nico De

doi:10.1007/s00125-019-4969-z

Cited by 48 publications

(36 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…hAECs have been shown to promote vessel formation in vitro and angiogenesis in vivo, in correlation with the expression of numerous angiogenic factors directly involved in the revascularization process, such as vascular endothelial growth factor‐A (VEGF‐A), platelet‐derived growth factor subunit B (PDGF‐B), and angiopoietin‐1 (ANGPT1) . Among these factors, the VEGF family is known to stimulate the migration of endothelial cells and improve vascular permeability . It has been shown that a combination of VEGF‐A and PDGF‐B promotes islet engraftment in mice in extrahepatic sites.…”

Section: Discussionmentioning

confidence: 99%

Shielding islets with human amniotic epithelial cells enhances islet engraftment and revascularization in a murine diabetes model

Lebreton

Bellofatto

Wassmer

et al. 2020

American Journal of Transplantation

View full text Add to dashboard Cite

Hypoxia is a major cause of considerable islet loss during the early posttransplant period. Here, we investigate whether shielding islets with human amniotic epithelial cells (hAECs), which possess anti‐inflammatory and regenerative properties, improves islet engraftment and survival. Shielded islets were generated on agarose microwells by mixing rat islets (RIs) or human islets (HI) and hAECs (100 hAECs/IEQ). Islet secretory function and viability were assessed after culture in hypoxia (1% O2) or normoxia (21% O2) in vitro. In vivo function was evaluated after transplant under the kidney capsule of diabetic immunodeficient mice. Graft morphology and vascularization were evaluated by immunohistochemistry. Both shielded RIs and HIs show higher viability and increased glucose‐stimulated insulin secretion after exposure to hypoxia in vitro compared with control islets. Transplant of shielded islets results in considerably earlier normoglycemia and vascularization, an enhanced glucose tolerance, and a higher β cell mass. Our results show that hAECs have a clear cytoprotective effect against hypoxic damages in vitro. This strategy improves β cell mass engraftment and islet revascularization, leading to an improved capacity of islets to reverse hyperglycemia, and could be rapidly applicable in the clinical situation seeing that the modification to HIs are minor.

show abstract

Section: Discussionmentioning

confidence: 99%

Shielding islets with human amniotic epithelial cells enhances islet engraftment and revascularization in a murine diabetes model

Lebreton

Bellofatto

Wassmer

et al. 2020

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…The expression of EPO was positively correlated with VEGF. VEGFa is one of the founding members of VEGF, which is crucial in blood vessels maintenance [33] . Attenuation of blood vessels is one of the typical manifestations of RP fundus, which indicates the poor blood supply of the retina.…”

Section: Discussionmentioning

confidence: 99%

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

Zhang

Dai

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Retinitis pigmentosa (RP) is the most common cause of blindness in retinal disease. Long-lasting ocular administration is an effective therapy to delay the progression of RP. And hydrogel sustained release system may be an available and stable drug carrier in the treatment of RP.Method Hydrogel sustained release system was constructed as a drug carrier of recombinant human erythropoietin (rhEPO). We administered retinal degenerative (rd) mice (Pdeb rd1 / Pdeb rd1 ) via subconjunctival or retrobulbar injection at postnatal 2 weeks (PN-2w), examined the mice and tested the factors of retina at two weeks after injection. Electroretinogram (ERG) was used to examine retinal function at PN-4w, western blot and q-PCR were used to test the expression of Bax, Bcl-2, iNOS and VEGFa of retina.Result Photoreceptor apoptosis were alleviated in all rhEPO administrated groups. The retinal blood supply was improved in injection groups. Compared with placebo and blank control groups, rhEPO treatment could enhance the retinal function and delay the progression of disease. Although there was no significant difference between rhEPO hydrogel and rhEPO treated group, photoreceptor apoptosis in rhEPO hydrogel group was less than that in rhEPO group, and the retinal function was better in rhEPO hydrogel group. Moreover, different routes of administration might have little effect on treatment in this research.Conclusion Early intervention can effectively control the progression of the disease. Anti-apoptosis,neuroprotection and erythropoietin of rhEPO could be useful in the treatment of RP. Hydrogel as a long-lasting drug sustained release system was stable and available, and might become a potential drug carrier in the future.

show abstract

“…3,8 Although the binding affinity of VEGF-A to VEGFR-1 is much higher than that to VEGFR-2, VEGFR-2 plays a decisive role in angiogenesis in NSCLC. 9 In contrast, VEGFR-1 is not relevant in adults' physiological angiogenesis, while it assists tumor angiogenesis, as the overexpression of VEGFR-1 and PlGF can improve the cell invasiveness and drug resistance of NSCLC. 8,10 There is evidence that high VEGFR-1 expression associates with low survival rate in patients with NSCLC.…”

Section: Tumor Angiogenesis In Nsclcmentioning

confidence: 99%

“…Finally, the phosphoinositide 3 kinase (PI3K)/Akt signaling pathway is activated via multiple pathways. The activation of Akt is associated with EC survival and the upregulation of endothelial nitric oxide synthase (eNOS) which further increases vessel permeability 9,13,14 (Figure 1).…”

Section: Tumor Angiogenesis In Nsclcmentioning

confidence: 99%

<p>Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer</p>

Tian¹,

Cao²,

Shu³

et al. 2020

OTT

View full text Add to dashboard Cite

Angiogenesis plays an essential role in the development of most solid tumors by delivering nutrients and oxygen to the tumor. Therefore, anti-angiogenic therapy, particularly anti-VEGF and anti-VEGF receptor (VEGFR) therapy, has been a popular strategy to treat cancer. However, anti-angiogenic therapy does not significantly improve patients' outcomes when used alone because the cutdown of the vessels transforms tumor cells to a hypoxiatolerant phenotype. While combining anti-angiogenic therapy with other therapies, including chemotherapy, radiotherapy, immunotherapy, and anti-epidermal growth factor receptor (EGFR) therapy, has a promising efficacy due to the vessel normalization effect induced by anti-angiogenic agents. Here, we review the characteristics of tumor angiogenesis, the mechanisms, clinical applications, and prospects of combining anti-angiogenic therapy with other therapies in the treatment of non-small cell lung cancer.

show abstract

VEGF-A and blood vessels: a beta cell perspective

Cited by 48 publications

References 66 publications

Shielding islets with human amniotic epithelial cells enhances islet engraftment and revascularization in a murine diabetes model

Shielding islets with human amniotic epithelial cells enhances islet engraftment and revascularization in a murine diabetes model

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

<p>Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer</p>

Contact Info

Product

Resources

About